Author(s): Dessinioti C, Zisimou C, Tzanetakou V, Stratigos A, Antoniou C
BACKGROUND: Limited data exist on the use of systemic antibiotic treatment for hidradenitis supportive (HS).
AIM: To investigate the effectiveness, safety and relapse rate of HS treated with a combination of daily oral clindamycin and rifampicin.
METHODS: This was a prospective, hospital-based study of oral clindamycin 600 mg and rifampicin 600 mg daily for 12 weeks for treatment of HS. Patients were followed up for 1 year to monitor for relapse.
RESULTS: In total, 26 patients with HS received oral clindamycin and rifampicin. Most were overweight or obese (73%), and most were smokers (88%). After 12 weeks, clinical response was noted in 19 patients (73%). Response was associated only with female sex (P = 0.02), and not with body mass index, Hurley stage or lesion location. Eight patients (31%) experienced adverse events. At the 1-year follow-up, there was sustained efficacy in 7 (41%) patients, while 10 (59%) had disease relapse after a mean time of 4.2 months.
CONCLUSIONS: Oral clindamycin with oral rifampicin for 12 weeks is an effective and tolerable regimen for HS.
Dermatology Journal and/or Publisher
Journal Name: Clinical and experimental dermatology
Journal Abbreviation: Clin. Exp. Dermatol.
Journal Date Published: 2016-10-18
National Center for Biotechnology Information
PMID: 27753139
Article Source: http://www.ncbi.nlm.nih.gov/pubmed/27753139
Lasted Revision: 2016-12-19
Abstract Source: National Center for Biotechnology Information, U.S. National Library of Medicine Abstract Query for Hidradenitis suppurativa (HS).
